The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study.
 
Richard M. Lee-Ying
Honoraria - Amgen; Janssen
Consulting or Advisory Role - Amgen; AstraZeneca Canada; Bayer; Bristol-Myers Squib; Celgene; Eisai; Ipsen; Ipsen; Janssen; Merck; Pfizer; Sanofi
Speakers' Bureau - Amgen; Celgene; Janssen
Research Funding - Sanofi
 
Calogero Saieva
No Relationships to Disclose
 
Pier Vitale Nuzzo
No Relationships to Disclose
 
Andrea Malgeri
No Relationships to Disclose
 
Giuseppe Fotia
No Relationships to Disclose
 
Elisa Zanardi
Honoraria - Bristol-Myers Squibb/Pfizer
Consulting or Advisory Role - Astellas Pharma; Ipsen; Janssen Oncology
Speakers' Bureau - Bristol-Myers Squibb/Pfizer
Travel, Accommodations, Expenses - Janssen Oncology
 
Sabrina Rossetti
No Relationships to Disclose
 
Loana Bueno Valenca
No Relationships to Disclose
 
Anna Patrikidou
No Relationships to Disclose
 
Mikol Modesti
No Relationships to Disclose
 
Thiago Martins Oliveira
No Relationships to Disclose
 
Sandro Pignata
Honoraria - AstraZeneca; MSD; pfizer; pharmamar; Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Pfizer; PharmaMar; Roche; tesaro
Research Funding - AstraZeneca (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
Giuseppe Fornarini
No Relationships to Disclose
 
Giuseppe Procopio
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb (BMS); Eisai; Ipsen; Janssen; Merck Sharp & Dohme; MSD Oncology; Novartis; Pfizer
Research Funding - Astellas Pharma; Ipsen; Janssen Oncology
 
Daniele Santini
No Relationships to Disclose
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; POINT Biopharma; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Ugo De Giorgi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dompé Farmaceutici; Eisai; Ipsen; Janssen; Merck KGaA; MSD; Novartis; Pfizer; PharmaMar
Research Funding - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Pfizer
 
Antonio Russo
No Relationships to Disclose
 
Edoardo Francini
Honoraria - Janssen-Cilag
Research Funding - Roche
Travel, Accommodations, Expenses - Janssen-Cilag